| Literature DB >> 28694983 |
Daniele Volpe1, Elisa Pelosin2, Leila Bakdounes1, Stefano Masiero3, Giannettore Bertagnoni4, Chiara Sorbera1, Maria Giulia Giantin1.
Abstract
BACKGROUND: Proprioceptive deficits have been largely documented in PD patients, thus external sensory signals (peripheral sensory feedback) are often used to compensate the abnormalities of proprioceptive integration. This pilot study aims to evaluate the feasibility and the effectiveness of a rehabilitation-training program, combined with the use of a sensory-motor orthotic in improving balance in a small sample of PD patients.Entities:
Keywords: Parkinson’s disease; Postural instability; Rehabilitation; Sensory-motor orthotic
Year: 2017 PMID: 28694983 PMCID: PMC5498915 DOI: 10.1186/s40734-017-0058-y
Source DB: PubMed Journal: J Clin Mov Disord ISSN: 2054-7072
Fig. 1Example of the sensory-motor orthotic
KNGF Guidelines: physiotherapy program for balance training
| Improvement of physical capacity | To maintain or to improve physical capacity with training of aerobic muscle strength (with the emphasis on the muscles of the trunk and legs), joint mobility (among others, axial) and muscle length (among others, muscles of the calf and the hamstrings, flexor and extensor of the knee) |
| Improvement of the transfers | To train transfers by applying cognitive improvement strategies and cues to initiate and continue movements |
| Normalizing body posture | To prevent or treat postural deformities with exercises for postural alignment and coordinated movements |
| Training balance | To optimize balance during the performance of activities in static and dynamic conditions with exercises for training strength and perturbation-based balance training with emphasis of functional reaching test in protected condition and how to activate postural responses to perturbation. Falls prevention strategies. |
| Gait training | To walk safely and to increase (comfortable) walking speed with exercise walking with the use of cues and cognitive movement strategies and to train muscle strength and mobility of the trunk and upper and lower limbs. |
Baseline demographic and clinical variables of the two groups enrolled in the study
| EXP Group | CTRL Group | Statistics | |
|---|---|---|---|
| mean ± SD | mean ± SD | Baseline | |
| Gender (M/F) | 7/3 | 5/3 | |
| Age (yr) | 69.18 ± 7.61 | 63.37 ± 6.89 |
|
| Height (cm) | 160.91 ± 9.58 | 160.62 ± 14.74 |
|
| Weight (kg) | 69.54 ± 13.33 | 67.62 ± 8.31 |
|
| Disease duration (yr) | 7.82 ± 4.00 | 8.12 ± 2.90 |
|
| Falls (n) | 1.45 ± 2.16 | 0.87 ± 0.99 |
|
| Levodopa (mg/day) | 455.32 ± 355.49 | 409.19 ± 340.68 |
|
| • | |||
| Pramipexole E.R. |
|
| N.A. |
| Ropirinole E.R. |
|
| N.A. |
| Rotigotine ( |
|
| N.A. |
| Rasagiline ( |
|
| N.A. |
| • | |||
| Entacapone |
|
| N.A. |
| Selegiline |
|
| N.A. |
| Amantadine |
|
| N.A. |
Exp, Experimental; CTRL, Control; M, Male; F, Female; Yr, Years; Cm, centimeters; Kg, Kilograms; Mg = Milligrams; N, number; ER = Extended Released; N.A., Not Applicable
Clinical variables of the two groups enrolled in the study and their comparisons at each time point
| PSM Group | CTRL Group | Statistic | |
|---|---|---|---|
| Motor UPDRS section III at T0-Baseline | 40.87 ± 6.01 | 39.00 ± 11.89 | |
| Motor UPDRS section III at T1-Discharge | 37.12 ± 6.66 | 36.90 ± 12.02 |
|
| Motor UPDRS section III at T2-Follow up | 35.55 ± 6.57 | 36.80 ± 11.80 |
|
| Berg Balance Scale T0-Baseline | 45.63 ± 5.92 | 45.12 ± 4.58 | |
| Berg Balance Scale T1-Discharge | 49.3 ± 3.15 | 47.12 ± 5.05 |
|
| Berg Balance Scale T2-Follow up | 50.1 ± 2.72 | 49.37 ± 5.35 |
|
| Falls T0-Baseline | 1.45 ± 2.16 | 0.87 ± 0.99 | |
| Falls T1-Discharge | 0.45 ± 1.03 | 0.12 ± 0.31 |
|
| Falls T2-Follow up | 0.00 ± 0.00 | 0.00 ± 0.00 | N.A. |
| Timed Up and Go T0-Baseline | 13.08 ± 2.17 | 13.8 ± 3.43 | |
| Timed Up and Go T1-Discharge | 12.13 ± 1.35 | 12.8 ± 2.81 |
|
| Timed Up and Go T2-Follow up | 10.81 ± 1.07 | 13.2 ± 2.75 |
|
| 6MWT T0-Baseline | 305.64 ± 48.89 | 319.8 ± 48.59 | |
| 6MWT T1-Discharge | 335.64 ± 44.09 | 332.5 ± 66.00 |
|
| 6MWT T2-Follow up | 342.2 ± 59.99 | 328.38 ± 70.18 |
|
| PDQ-39 T0-Baseline | 57.7 ± 22.93 | 59 ± 14.38 | |
| PDQ-39 T1-Discharge | 54.36 ± 24.47 | 49.5 ± 20.52 |
|
| PDQ-39 T2-Follow up | 52.1 ± 27.44 | 51.25 ± 19.46 |
|
Exp, Experimental, CTRL Control, UPDRS Unified Parkinson Disease Rating Scale, 6MWT Six Meters Walking Test, PDQ-39 Parkinson’s Disease Questionnaire-39 items. N.A., not applicable
P values represent the post hoc analysis (T0 vs T1 and T0 vs T2) when a main effect of TIME was detected with Repeated Measures ANOVA
Fig. 3Sway area values during instrumental FRT-EC condition of the two groups enrolled in the study at each time point
Fig. 4Romberg index values during FRT condition of the two groups enrolled in the study at each time point